0001225208-22-006815.txt : 20220510
0001225208-22-006815.hdr.sgml : 20220510
20220510205438
ACCESSION NUMBER: 0001225208-22-006815
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220507
FILED AS OF DATE: 20220510
DATE AS OF CHANGE: 20220510
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: WANG HUIMIN
CENTRAL INDEX KEY: 0001204553
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-15525
FILM NUMBER: 22911784
MAIL ADDRESS:
STREET 1: C/O EDWARDS LIFESCIENCES
STREET 2: ONE EDWARDS WAY
CITY: IRVINE
STATE: CA
ZIP: 92614
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Edwards Lifesciences Corp
CENTRAL INDEX KEY: 0001099800
STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
IRS NUMBER: 364316614
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE EDWARDS WAY
CITY: IRVINE
STATE: CA
ZIP: 92614
BUSINESS PHONE: 9492502500
MAIL ADDRESS:
STREET 1: ONE EDWARDS WAY
CITY: IRVINE
STATE: CA
ZIP: 92614
FORMER COMPANY:
FORMER CONFORMED NAME: EDWARDS LIFESCIENCES CORP.
DATE OF NAME CHANGE: 20090225
FORMER COMPANY:
FORMER CONFORMED NAME: EDWARDS LIFESCIENCES CORP
DATE OF NAME CHANGE: 20000203
FORMER COMPANY:
FORMER CONFORMED NAME: CVG CONTROLLED INC
DATE OF NAME CHANGE: 19991126
4
1
doc4.xml
X0306
4
2022-05-07
0001099800
Edwards Lifesciences Corp
EW
0001204553
WANG HUIMIN
ONE EDWARDS WAY
IRVINE
CA
92614
1
CVP, Japan & Intercontinental
Common Stock
2022-05-07
4
F
0
363.0000
100.5200
D
97553.8018
D
Common Stock
2022-05-08
4
M
0
6956.0000
0
A
104509.8018
D
Common Stock
2022-05-08
4
F
0
4210.0000
100.5200
D
100299.8018
D
Common Stock
2022-05-09
4
M
0
3675.0000
35.1967
A
103974.8018
D
Common Stock
2022-05-09
4
S
0
3675.0000
98.7100
D
100299.8018
D
Performance Rights
2022-05-08
4
M
0
6956.0000
0.0000
D
2022-05-08
2026-05-07
Common Stock
6956.0000
0.0000
D
Employee Stock Option (Right to Acquire)
35.1967
2022-05-09
4
M
0
3675.0000
0.0000
D
2016-06-12
2023-05-11
Common Stock
3675.0000
33075.0000
D
On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4.
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 4, 2022.
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.
Linda J. Park, Attorney-in-Fact
2022-05-10